Total medical devices industry cross border M&A deals worth $2.2bn were announced in Europe in Q2 2022, led by ResMed’s $1bn acquisition of MediFox DAN Group, according to GlobalData’s deals database.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked an increase of 1312.3% over the previous quarter and a rise of 16.1% when compared with the last four-quarter average of $1.86bn.
Europe held an 80.30% share of the global medical devices industry cross border M&A deal value that totalled $2.69bn in Q2 2022. With a 66.17% share and deals worth $1.78bn, Germany was the top country in Europe’s cross border M&A deal value across medical devices industry.
In terms of deal activity, Europe recorded 36 cross border deals during Q2 2022, marking a decrease of 21.74% over the previous quarter and a rise of 17.07% over the last four-quarter average. Germany recorded nine deals during the quarter.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEurope medical devices industry cross border M&A deals in Q2 2022: Top deals
The top five medical devices industry cross border M&A deals accounted for 89.9% of the overall value during Q2 2022.
The combined value of the top five cross border M&A deals stood at $1.94bn, against the overall value of $2.2bn recorded for the quarter.
The top five medical devices industry cross border deals of Q2 2022 tracked by GlobalData were:
1) ResMed $1bn acquisition deal with MediFox DAN Group
2) The $541.63m acquisition of Phenox by Wallaby Medical
3) Integer $141.73m acquisition deal with Aran Biomedical
4) The $138.06m acquisition of SunshineSmile by Straumann
5) Cochlear $122.03m acquisition deal with Oticon Medical
